Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Kobayashi, Dione T ^a   Olson, Rory J ^b   Sly, Laurel ^c   Swanson, Chad J ^a   Chung, Brett ^a   Naryshkin, Nikolai ^d   Narasimhan, Jana ^d   Bhattacharyya, Anuradha ^d   Mullenix, Michael ^b   Chen, Karen S ^a  

^a Spinal Muscular Atrophy Foundation   (United States)

^b Enzo Life Sciences Inc   (United States)

^c PharmOptima   (United States)

^d PTC THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; BRAIN; CELL LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MOUSE; MUSCLE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SPINAL CORD; SPINAL MUSCULAR ATROPHY; TISSUE LEVEL; ADULT; AGED; ANIMAL; CELL CULTURE; FEMALE; IN VITRO STUDY; MALE; METABOLISM; METHODOLOGY; REPRODUCIBILITY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICE; MUSCULAR ATROPHY, SPINAL; REPRODUCIBILITY OF RESULTS; SMN COMPLEX PROTEINS;

EID: 80052333116     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024269     Document Type: Article

References (52)

1. Pearn J, (1980) Classification of spinal muscular atrophies. Lancet 1: 919-922.
2. Crawford TO, Pardo CA, (1996) The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 3: 97-110.
3. Pearn J, (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15: 409-413.
4. Hendrickson BC, Donohoe C, Akmaev VR, Sugarman EA, Labrousse P, et al. (2009) Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet 46: 641-644.
5. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155-165.
6. Lorson CL, Hahnen E, Androphy EJ, Wirth B, (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 96: 6307-6311.
7. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, et al. (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8: 1177-1183.
8. Cho S, Dreyfuss G, (2010) A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev 24: 438-442.
9. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, et al. (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16: 265-269.
10. Park GH, Kariya S, Monani UR, (2010) Spinal muscular atrophy: new and emerging insights from model mice. Curr Neurol Neurosci Rep 10: 108-117.
11. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, et al. (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12: 59-65.
12. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, et al. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12: 2481-2489.
13. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, et al. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98: 9808-9813.
14. Garbes L, Riessland M, Holker I, Heller R, Hauke J, et al. (2009) LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 18: 3645-3658.
15. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, et al. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54: 647-654.
16. Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, et al. (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 19: 1492-1506.
17. Hahnen E, Eyupoglu IY, Brichta L, Haastert K, Trankle C, et al. (2006) In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 98: 193-202.
18. Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, et al. (2009) Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med 1: 5ra12.
19. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR, (2007) Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 5: e73.
20. Mattis VB, Rai R, Wang J, Chang CW, Coady T, et al. (2006) Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet 120: 589-601.
21. Singh NK, Singh NN, Androphy EJ, Singh RN, (2006) Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26: 1333-1346.
22. Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, et al. (2004) Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 114: 1726-1731.
23. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, et al. (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.
24. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, et al. (2010) CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120: 1253-1264.
25. Chang HC, Hung WC, Chuang YJ, Jong YJ, (2004) Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem Int 45: 1107-1112.
26. Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, et al. (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 10: 2841-2849.
27. Angelozzi C, Borgo F, Tiziano FD, Martella A, Neri G, et al. (2008) Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 45: 29-31.
28. Butchbach ME, Singh J, Thorsteinsdottir M, Saieva L, Slominski E, et al. (2010) Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 19: 454-467.
29. Grzeschik SM, Ganta M, Prior TW, Heavlin WD, Wang CH, (2005) Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 58: 194-202.
30. Jarecki J, Chen X, Bernardino A, Coovert DD, Whitney M, et al. (2005) Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 14: 2003-2018.
31. Singh J, Salcius M, Liu SW, Staker BL, Mishra R, et al. (2008) DcpS as a therapeutic target for spinal muscular atrophy. ACS Chem Biol 3: 711-722.
32. Kolb SJ, Gubitz AK, Olszewski RF Jr, Ottinger E, Sumner CJ, et al. (2006) A novel cell immunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol 6: 6.
33. Piepers S, Cobben JM, Sodaar P, Jansen MD, Wadman RI, et al. (2011) Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. J Neurol Neurosurg Psychiatry 82 (8): 850-852.
34. Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, et al. (2006) SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 66: 1067-1073.
35. Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G, (1998) A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 95: 615-624.
36. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, et al. (2005) SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14: 845-857.
37. Nguyen thi M, Humphrey E, Lam LT, Fuller HR, Lynch TA, et al. (2008) A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Neurology 71: 1757-1763.
38. Patrizi AL, Tiziano F, Zappata S, Donati MA, Neri G, et al. (1999) SMN protein analysis in fibroblast, amniocyte and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis. Eur J Hum Genet 7: 301-309.
39. Sproule DM, Punyanitya M, Shen W, Dashnaw S, Martens B, et al. (2011) Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophy. J Child Neurol 26: 309-317.
40. Elsasser-Beile U, Dursunoglu B, Gallati H, Monting JS, von Kleist S, (1995) Comparison of cytokine production in blood cell cultures of healthy children and adults. Pediatr Allergy Immunol 6: 170-174.
41. Battaglia G, Princivalle A, Forti F, Lizier C, Zeviani M, (1997) Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Hum Mol Genet 6: 1961-1971.
42. Lorson MA, Spate LD, Prather RS, Lorson CL, (2008) Identification and characterization of the porcine (Sus scrofa) survival motor neuron (SMN1) gene: an animal model for therapeutic studies. Dev Dyn 237: 2268-2278.
43. Lorson MA, Spate LD, Samuel MS, Murphy CN, Lorson CL, et al. (2011) Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA. Transgenic Res [Epub ahead of print]. doi:10.1007/s11248-011-9496-8.
44. Wishart TM, Huang JP, Murray LM, Lamont DJ, Mutsaers CA, et al. (2010) SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet 19: 4216-4228.
45. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, et al. (2007) Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117: 659-671.
46. Williams JH, Schray RC, Patterson CA, Ayitey SO, Tallent MK, et al. (2009) Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci 29: 7633-7638.
47. Rudnik-Schoneborn S, Vogelgesang S, Armbrust S, Graul-Neumann L, Fusch C, et al. (2010) Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Muscle Nerve 42: 144-147.
48. Araujo Ade Q, Araujo M, Swoboda KJ, (2009) Vascular perfusion abnormalities in infants with spinal muscular atrophy. J Pediatr 155: 292-294.
49. Park GH, Maeno-Hikichi Y, Awano T, Landmesser LT, Monani UR, (2010) Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J Neurosci 30: 12005-12019.
50. Frugier T, Nicole S, Cifuentes-Diaz C, Melki J, (2002) The molecular bases of spinal muscular atrophy. Curr Opin Genet Dev 12: 294-298.
51. Gabanella F, Carissimi C, Usiello A, Pellizzoni L, (2005) The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum Mol Genet 14: 3629-3642.
52. El-Khodor BF, Edgar N, Chen A, Winberg ML, Joyce C, et al. (2008) Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp Neurol 212: 29-43.